ANAB Stock Recent News
ANAB LATEST HEADLINES
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Cantor Global Healthcare Conference 2025, New York, NY Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, Sept. 3, 2025 at 8:00am ET / 5:00am PT 2025 Wells Fargo Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetings Date and Time – Thursday, Sept.
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.71 per share a year ago.
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
Rosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is secured. Key risks include future cash needs, execution challenges, and tough competition, so I maintain a 2/5 conviction and keep ANAB in my speculative portfolio.
AnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also being evaluated in a phase 2 trial for moderate-to-severe ulcerative colitis, targeting a $15.8B global market, with data expected in Q4 2025. ANAB has sufficient cash for at least 12 months but may need to raise additional funds, potentially via an existing $100M ATM agreement.
AnaptysBio, Inc. ANAB on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis.
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period. Furthermore, responses were then durable for at least two months off drug. Rosnilimab was safe and well tolerated, particularly when compared to standard of care biologics or JAKs.
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT.
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1.64 per share a year ago.